초록 열기/닫기 버튼
This randomized, double-blind, placebo-controlled, crossover human study aimed to investigate the efficacy ofID-GMG001 for the alleviation of hangover in men between the ages of 20 and 50 years. The selected subjects wererandomized to an ID-GMG001 group and a placebo group. Two overnight assessments were conducted at KyungheeUniversity Hospital exactly one week apart and at the same time of day. The subjects ingested placebo or ID-GMG001and then consumed alcohol 30 minutes later to induce hangover. The efficacy of ID-GMG001 for alleviating hangover wasdetermined based on serum acetaldehyde levels over time. After the experiment, the results of 21 subjects who met theassessment criteria (per-protocol set) were analyzed. Comparisons of area under the curve (AUC; p=0.032), dose at 4 and6 hours after alcohol consumption (p=0.001 and p=0.008, respectively), showed that serum acetaldehyde concentrationswere significantly lower in the ID-GMG001 group than in the placebo group. A safety assessment revealed no serious IDGMG001-related adverse events, and no significant changes in vital signs and laboratory parameters occurred that couldhave affected patient safety. In conclusion, we determined that the use of ID-GMG001 before alcohol consumptioneffectively alleviates hangover in adults by reducing serum acetaldehyde concentrations.
